Gilead Sciences Inc.
Gilead Sciences Announces Departure of Chief Medical Officer Merdad Parsey
Summary
Gilead Sciences, Inc. announced on July 17, 2024, that Chief Medical Officer Merdad V. Parsey, M.D., Ph.D., will leave the company early next year. Dr. Parsey will continue in his role until Q1 2025 while the company identifies a successor. During his tenure, Dr. Parsey led the growth of Gilead's global clinical development and medical affairs organizations, contributing significantly to the company's pipeline advancements in virology, oncology, and inflammation.
Profitelligence Alerts
Get alerts for GILD
Be first to know when Gilead Sciences Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Official SEC Documents
Advertisement